

In the Claims

This listing of the claims will replace all prior versions, and listings, of claims in the application:


Claims 1-26 are pending in this Application.

Claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 13, 14, 15, 16, 17, 18, 19, and 24 **(currently amended)**

Claims 10, 11, 20, 21, 22, 23, 25, and 26 **(cancelled)**

Claims 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, and 38 **(new)**

1. **(currently amended)** A compound represented by formula **I**,



or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt, ~~hydrate, or prodrug~~ thereof, and wherein,

each W is independently N or CR¹;

each R¹ is independently selected from -H, halogen, trihaloalkyl, -CN, -NH₂, -NO₂, -OR⁶, -N=CNR⁶R⁷, -N(R⁶)C(=NR⁸)NR⁶R⁷, -SR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -C(O)N(OR⁶)R⁷, -C(=NR⁸)NR⁶R⁷, -N(R⁶)SO₂R⁷, ~~NC(O)R⁶, NCO₂R⁶~~, -C(O)R⁷, -R⁷, and -A-R⁷; provided at least one of R¹ is -A-R⁷, wherein, only for said at least one -A-R⁷, R⁷ must be an ~~optionally substituted~~ heteroalicyclic ring, and any nitrogen of said optionally substituted heteroalicyclic ring cannot be directly bound to A, and where the heteroalicyclic ring of -A-R⁷ is optionally substituted with one to five groups independently selected from alkyl, aryl, arylalkyl, heterocyclalkyl, heterocycl, alkoxy,

substituted alkoxy, methylenedioxy, amino, alkylamino, dialkylamino, amidino, aryloxy, arylalkyloxy, carboxy, acyloxy, benzyloxycarbonylamino, cyano, acyl, halogen, hydroxy, nitro, sulfanyl, sulfinyl, sulfonyl, halogen, hydroxy, oxo, carbamyl, and acylamino;

A is O, S(O)₀₋₂, and NR⁶;

L is O, S(O)₀₋₂, or NR³;

Q is C or N, when Q is N, then R⁴ does not exist;

R² and R³ are each independently -H or -R⁷;

R⁴ and R⁵ are each independently selected from -H, -OR⁶, -NR⁶R⁷, -S(O)₀₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -N(R⁶)SO₂R⁶, ~~NC(O)R⁶, -NCO₂R⁶, -C(O)R⁷,~~ -CN, -NO₂, -NH₂, halogen, trihalomethyl, and -R⁷; or

R⁴ and R⁵, when taken together, form a five or six-membered aromatic ring system containing between zero and two nitrogens, said five or six-membered aromatic ring system optionally substituted with between zero and four of R¹⁵;


R⁶ is selected from -H, ~~optionally substituted~~ C₁₋₈alkyl, ~~optionally substituted~~ arylC₁₋₈alkyl, ~~optionally substituted~~ heterocyclylC₁₋₈alkyl, ~~optionally substituted~~ aryl, and ~~optionally substituted~~ heterocyclyl;

R⁷, for other than R⁷ in -A-R⁷, is selected from -H, ~~optionally substituted~~ C₁₋₈alkyl, ~~optionally substituted~~ arylC₁₋₈alkyl, ~~optionally substituted~~ heterocyclylC₁₋₈alkyl, ~~optionally substituted~~ aryl, and ~~optionally substituted~~ heterocyclyl; provided that there are at least two carbons between any heteroatom of R⁷ and A ~~or either nitrogen to which~~ R² [[or]]and R³ are attached; or

R⁶ and R⁷, when taken together with a common nitrogen to which they are attached, form ~~an optionally substituted~~ five- to seven-membered heterocyclic ring, said ~~optionally substituted~~ five- to seven-membered heterocyclic ring optionally containing at least one additional heteroatom selected from nitrogen, oxygen, sulfur, and phosphorus;

R⁸ is -H, -NO₂, -CN, -OR⁶, and ~~optionally substituted~~ C₁₋₈alkyl;

X is selected from one of the following six formulae:



wherein m is zero to five, n is zero to three, and Z is N or CR¹⁰;

R¹⁰ is selected from -H, halogen, trihalomethyl, -NH₂, -NO₂, -OR⁶, -N=CNR⁶R⁷, -NR⁶R⁷, -N(R⁶)C(=NR⁸)NR⁶R⁷, -SR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -C(O)N(OR⁶)R⁷, -C(=NR⁸)NR⁶R⁷, -N(R⁶)SO₂R⁶, ~~NC(O)R⁶~~, ~~NCO₂R⁶~~, -C(O)R⁷, and R⁷;

K is O, S, or NR¹¹;

R¹¹ is selected from cyano, -NO₂, -OR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -C(O)N(OR⁶)R⁷, -C(O)R⁷, and R⁶; and

each R¹⁵ is independently selected from -H, halogen, -NH₂, -NO₂, -OR⁶, -N=CNR⁶R⁷, -NR⁶R⁷, -N(R⁶)C(=NR⁸)NR⁶R⁷, -SR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -C(O)N(OR⁶)R⁷, -C(=NR⁸)NR⁶R⁷, -N(R⁶)SO₂R⁶, ~~NC(O)R⁶~~, ~~NCO₂R⁶~~, -C(O)R⁷, and R⁷.

2. **(currently amended)** The compound according to claim 1, wherein L is NR³; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

3. **(currently amended)** The compound according to claim 2, wherein K is either O or NR¹¹; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

4. **(currently amended)** The compound according to claim 3, wherein R² and R³ are each independently selected from -H and ~~optionally substituted C₁₋₈alkyl~~, ~~wherein~~

~~substitution on the C₁₋₈alkyl of optionally substituted C₁₋₈alkyl is selected from NH₂, NO₂, OR⁶, N=CNR⁶R⁷, NR⁶R⁷, N(R⁶)C(=NR⁸)NR⁶R⁷, SR⁶, S(O)₁₋₂R⁶, SO₂NR⁶R⁷, CO₂R⁶, C(O)NR⁶R⁷, C(O)N(OR⁶)R⁷, C(=NR⁸)NR⁶R⁷, N(R⁶)SO₂R⁶, NC(O)R⁶, NCO₂R⁶, C(O)R⁷, heterocyclic, alicyclic, and aryl; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.~~


5. **(currently amended)** The compound according to claim 4, wherein R² and R³ are -H; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

6. **(currently amended)** The compound according to claim 5, wherein only one of R¹ is -A-R⁷, where A is selected from O, S(O)₀₋₁, and NR⁶; and for -A-R⁷, R⁷ is an optionally substituted heteroalicyclic ring optionally substituted with one to five groups independently selected from alkyl, aryl, arylalkyl, heterocyclalkyl, heterocycl, alkoxy, substituted alkoxy, methylenedioxy, amino, alkylamino, dialkylamino, amidino, aryloxy, arylalkyloxy, carboxy, acyloxy, benzyloxycarbonylamino, cyano, acyl, halogen, hydroxy, nitro, sulfanyl, sulfinyl, sulfonyl, halogen, hydroxy, oxo, carbamyl, and acylamino; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

7. **(currently amended)** The compound according to claim 6, wherein R⁶ is selected from -H and C₁₋₈alkyl; ~~said C₁₋₈alkyl optionally substituted with one or more groups each independently selected from NH₂, NO₂, OR⁶, N=CNR⁶R⁷, NR⁶R⁷, N(R⁶)C(=NR⁸)NR⁶R⁷, SR⁶, S(O)₁₋₂R⁶, SO₂NR⁶R⁷, CO₂R⁶, C(O)NR⁶R⁷, C(O)N(OR⁶)R⁷, C(=NR⁸)NR⁶R⁷, N(R⁶)SO₂R⁶, NC(O)R⁶, NCO₂R⁶, C(O)R⁷, heterocyclic, alicyclic, and aryl; and R⁷ of -A-R⁷ is selected from the following optionally substituted heteroalicyclics: azetidine, perhydroazepinyl, piperidinyl, piperazinyl, azabicyclo[3.2.1]octyl, octahydro-cyclopenta[c]pyrroleyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, pyrrolidinyl, dihydropyridinyl, tetrahydropyridinyl, quinuclidinyl,~~


tetrahydrofuranyl, tetrahydropyranyl, thiamorpholinyl sulfone, and dioxaphospholanyl; where the heteroalicyclic is optionally substituted with one to five groups independently selected from alkyl, aryl, arylalkyl, heterocyclalkyl, heterocycl, alkoxy, substituted alkoxy, methylenedioxy, amino, alkylamino, dialkylamino, amidino, aryloxy, arylalkyloxy, carboxy, acyloxy, benzyloxycarbonylamino, cyano, acyl, halogen, hydroxy, nitro, sulfanyl, sulfinyl, sulfonyl, halogen, hydroxy, oxo, carbamyl, and acylamino; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

8. (currently amended) The compound according to claim 7, wherein X is



m is 0 to 3, and R^{10} is selected from -H, halogen, $-NH_2$, $-NO_2$, $-OR^6$, $-N=CNR^6R^7$, $-NR^6R^7$, $-N(R^6)C(=NR^8)NR^6R^7$, $-SR^6$, $-S(O)_{1-2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-C(O)N(OR^6)R^7$, $-C(=NR^8)NR^6R^7$, $-N(R^6)SO_2R^6$, $-NC(O)R^6$, $-NCO_2R^6$, $-C(O)R^7$, and optionally substituted C_{1-8} alkyl; ~~said C_{1-8} alkyl optionally substituted with one or more groups each independently selected from $-NH_2$, $-NO_2$, $-OR^6$, $-N=CNR^6R^7$, $-NR^6R^7$, $-N(R^6)C(=NR^8)NR^6R^7$, $-SR^6$, $-S(O)_{1-2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-C(O)N(OR^6)R^7$, $-C(=NR^8)NR^6R^7$, $-N(R^6)SO_2R^6$, $-NC(O)R^6$, $-NCO_2R^6$, $-C(O)R^7$, heterocyclic, alicyclic, and aryl; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.~~

9. (currently amended) ~~The A compound according to claim 8, of formula II:~~



II

or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof;

wherein:

A, R⁴, R⁵, R¹⁰, and m are as defined above;

A is selected from O, S(O)₀₋₁, and NR⁶;

R⁷, in -A-R⁷, is selected from ~~optionally substituted~~ perhydroazepinyl, ~~optionally substituted~~ piperidinyl, ~~optionally substituted~~ pyrrolidinyl, and ~~optionally substituted~~ azetidine; wherein the ring nitrogen of R⁷ is substituted with a group R¹²; and R¹² is selected from a) -H, b) ~~optionally substituted~~ C₁₋₈alkyl, c) -SO₂R⁶, d) -SO₂NR⁶R⁷, e) -CO₂R⁶, f) -C(O)NR⁶R⁷, g) -C(O)R⁷, and h) ~~an optionally substituted~~ three- or four-carbon bridge between the ring nitrogen of R⁷ and a carbon vicinal to the ring nitrogen of R⁷; said three- or four-atom bridge optionally containing an oxygen in substitution for a carbon of the bridge; and where the C₁₋₈alkyl in b) and the bridge in h) are optionally substituted with one to five groups independently selected from alkyl, aryl, arylalkyl, heterocyclalkyl, heterocycl, alkoxy, substituted alkoxy, methylenedioxy, amino, alkylamino, dialkylamino, amidino, aryloxy, arylalkyloxy, carboxy, acyloxy, benzyloxycarbonylamino, cyano, acyl, halogen, hydroxy, nitro, sulfanyl, sulfinyl, sulfonyl, halogen, hydroxy, oxo, carbamyl, and acylamino;

R⁶ is selected from -H and C₁₋₈alkyl;

R⁴ and R⁵ are each independently selected from -H, -OR⁶, -NR⁶R⁷, -S(O)₀₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -N(R⁶)SO₂R⁶, -C(O)R⁷, -CN, -NO₂, -NH₂, halogen, trihalomethyl, and -R⁷; or

R⁴ and R⁵, when taken together, form a five or six-membered aromatic ring system containing between zero and two nitrogens, said five or six-membered aromatic ring system optionally substituted with between zero and four of R¹⁵;

R¹⁰ is selected from -H, halogen, -NH₂, -NO₂, -OR⁶, -N=CNR⁶R⁷, -NR⁶R⁷, -N(R⁶)C(=NR⁸)NR⁶R⁷, -SR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -C(O)N(OR⁶)R⁷, -C(=NR⁸)NR⁶R⁷, -N(R⁶)SO₂R⁶, -C(O)R⁷, and C₁₋₈alkyl;

m is 0 to 3;

R⁷, for other than R⁷ in A-R⁷, is selected from -H, C₁₋₈alkyl, arylC₁₋₈alkyl, heterocyclylC₁₋₈alkyl, aryl, and heterocyclyl;


R⁸ is -H, -NO₂, -CN, -OR⁶, and C₁₋₈alkyl; and

each R¹⁵ is independently selected from -H, halogen, -NH₂, -NO₂, -OR⁶, -N=CNR⁶R⁷, -NR⁶R⁷, -N(R⁶)C(=NR⁸)NR⁶R⁷, -SR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -C(O)N(OR⁶)R⁷, -C(=NR⁸)NR⁶R⁷, -N(R⁶)SO₂R⁶, -C(O)R⁷, and R⁷.

10. (canceled)

11. (canceled)

12. (currently amended) A The compound according to elaim 11, of formula III.



III

or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof;

where

R¹² is a C₁₋₄alkylene;

R¹³ is selected from -H, an alkoxy group, amino, alkylamino, dialkylamino, and an heteroalicyclic, with the proviso that a heteroatom of said alkoxy group, amino group, alkylamino group, dialkylamino group, and heteroalicyclic cannot be attached to a carbon of R¹² which is directly attached to the ring nitrogen of the piperidine in formula III;

R^4 and R^5 are each independently selected from -H, -OR⁶, -NR⁶R⁷, -S(O)₀₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -N(R⁶)SO₂R⁶, -C(O)R⁷, -CN, -NO₂, -NH₂, halogen, trihalomethyl, and -R⁷; or

R^4 and R^5 , when taken together, form a five or six-membered aromatic ring system containing between zero and two nitrogens, said five or six-membered aromatic ring system optionally substituted with between zero and four of R¹⁵;

R⁶ is selected from -H and C₁₋₈alkyl;

R⁷ is selected from -H, C₁₋₈alkyl, arylC₁₋₈alkyl, heterocyclylC₁₋₈alkyl, aryl, and heterocyclyl;


R⁸ is -H, -NO₂, -CN, -OR⁶, and C₁₋₈alkyl;

R¹⁰ is selected from -H, halogen, -NH₂, -NO₂, -OR⁶, -N=CNR⁶R⁷, -NR⁶R⁷, -N(R⁶)C(=NR⁸)NR⁶R⁷, -SR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -C(O)N(OR⁶)R⁷, -C(=NR⁸)NR⁶R⁷, -N(R⁶)SO₂R⁶, -C(O)R⁷, and C₁₋₈alkyl;

m is 0 to 3; and

each R¹⁵ is independently selected from -H, halogen, -NH₂, -NO₂, -OR⁶, -N=CNR⁶R⁷, -NR⁶R⁷, -N(R⁶)C(=NR⁸)NR⁶R⁷, -SR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -C(O)N(OR⁶)R⁷, -C(=NR⁸)NR⁶R⁷, -N(R⁶)SO₂R⁶, -C(O)R⁷, and R⁷.

13. (currently amended) A ~~The compound according to claim 12~~ formula IIIa,



IIIa

or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof;

wherein R¹² is a C₂₋₄alkylene; ~~R¹³ is as defined above;~~

R¹³ is selected from -H, an alkoxy group, an amino group, an alkylamino group, a dialkylamino group and an heteroalicyclic;

R^{10} is[[is]] selected from -H, halogen, perfluoroalkyl, $-NH_2$, $-NO_2$, $-OR^6$, $-N=CNR^6R^7$, $-NR^6R^7$, $-N(R^6)C(=NR^8)NR^6R^7$, $-SR^6$, $-S(O)_{1-2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-C(O)N(OR^6)R^7$, $-C(=NR^8)NR^6R^7$, $-N(R^6)SO_2R^6$, ~~$-NC(O)R^6$, $-NCO_2R^6$~~ , $-C(O)R^7$;

R^4 and R^5 are each independently selected from -H, halogen, and C_{1-4} alkyl; or R^4 and R^5 combined are ~~an optionally substituted phenyl~~ where the phenyl is optionally substituted with one to five groups independently selected from alkyl, aryl, arylalkyl,

heterocyclalkyl, heterocycl, alkoxy, substituted alkoxy, methylenedioxy, amino, alkylamino, dialkylamino, amidino, aryloxy, arylalkyloxy, carboxy, acyloxy, benzyloxycarbonylamino, cyano, acyl, halogen, hydroxy, nitro, sulfanyl, sulfinyl, sulfonyl, halogen, hydroxy, oxo, carbamyl, and acylamino; and

m is 0-3;

R^6 is selected from -H and C_{1-8} alkyl, said C_{1-8} alkyl substituted with at least one of $-CO_2H$ and $-CO_2C_{1-8}$ alkyl;

R^7 is selected from -H, C_{1-8} alkyl, $arylC_{1-8}$ alkyl, $heterocyclC_{1-8}$ alkyl, aryl, and heterocycl; and

R^8 is -H, $-NO_2$, $-CN$, $-OR^6$, and C_{1-8} alkyl.





14. **(currently amended)** The compound according to claim 13, wherein R^{12} is an ethylene; R^{10} is halogen; R^4 and R^5 are each independently selected from -H, halogen, and C_{1-2} alkyl; and m is 1-3; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.






15. **(currently amended)** The compound according to claim 14, wherein each R^{10} is independently selected from fluorine and chlorine; R^4 and R^5 are each independently selected from -H and C_{1-2} alkyl; and m is 1-3; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

16. **(currently amended)** The compound according to claim 15, wherein each R^{10} is independently selected from fluorine and chlorine; R^4 and R^5 are each independently selected from -H and $-CH_3$; and m is 1-2; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.






17. **(currently amended)** The compound according to claim 16, wherein R¹⁰ is fluorine; R⁴ and R⁵ are each independently selected from -H and -CH₃; and m is 1; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

18. **(currently amended)** The compound according to claim[[1]] 17, selected from the following:

Entry	Name	Structure
1	(3Z)-3-[[5-(methoxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-5-[[1-(phenylmethyl)pyrrolidin-3-yl]amino]-1,3-dihydro-2H-indol-2-one	
2	(3Z)-5-[(1-ethylpiperidin-3-yl)amino]-3-[[5-(methoxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
3	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[5-(methoxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
4	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2H-indol-2-one	

Entry	Name	Structure
5	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[5-(methoxy)-1H-benzimidazol-2-yl][4-(methoxy)phenyl]methylidene]-1,3-dihydro-2H-indol-2-one	
6	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[5-(methoxy)-1H-benzimidazol-2-yl][4-methylphenyl]methylidene]-1,3-dihydro-2H-indol-2-one	
7	(3Z)-3-[1H-benzimidazol-2-yl[4-nitrophenyl]methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
8	(3Z)-3-[1H-benzimidazol-2-yl[4-(methoxy)phenyl]methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
9	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	






Entry	Name	Structure
10	(3Z)-3-[[5-(methoxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
11	(3Z)-3-[(4-aminophenyl)(1H-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
12	(3Z)-3-[1H-benzimidazol-2-yl(4-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
13	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl(4-methylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
14	(3Z)-5-[(1-ethylpiperidin-4-yl)oxy]-3-[[5-(methoxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2H-indol-2-one	






Entry	Name	Structure
15	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl[4-(methoxy)phenyl]methylidene]-1,3-dihydro-2H-indol-2-one	
16	(3Z)-3-[1H-benzimidazol-2-yl(4-fluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
17	(3Z)-3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
18	(3Z)-3-[1H-benzimidazol-2-yl(3-fluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
19	(3Z)-3-[1H-benzimidazol-2-yl(3-nitrophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	






Entry	Name	Structure
20	3-((Z)-1H-benzimidazol-2-yl)(5-((1-ethylpiperidin-4-yl)amino)-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)benzonitrile	
21	(3Z)-3-((3-aminophenyl)(1H-benzimidazol-2-yl)methylidene)-5-((1-ethylpiperidin-4-yl)amino)-1,3-dihydro-2H-indol-2-one	
22	(3Z)-3-((1H-benzimidazol-2-yl)(phenyl)methylidene)-5-(piperidin-4-ylamino)-1,3-dihydro-2H-indol-2-one	
23	3-((Z)-1H-benzimidazol-2-yl)(5-((1-ethylpiperidin-4-yl)amino)-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)benzenecarboximide	
24	(3Z)-3-((1H-benzimidazol-2-yl)(phenyl)methylidene)-5-((1-(2-(methyloxy)ethyl)piperidin-4-yl)amino)-1,3-dihydro-2H-indol-2-one	






Entry	Name	Structure
25	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
26	(3Z)-3-[1H-benzimidazol-2-yl[3-(methoxy)phenyl]methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
27	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
28	2-(2-{2-[(Z)-{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-3H-indol-3-ylidene}(phenyl)methyl]-1H-imidazol-4-yl}ethyl)-1H-isoindole-1,3(2H)-dione	
29	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-[(1-[2-(dimethylamino)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	






Entry	Name	Structure
30	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-[[1-(methylsulfonyl)piperidin-4-yl]amino]-1,3-dihydro-2H-indol-2-one	
31	(3Z)-5-(8-azabicyclo[3.2.1]oct-3-ylamino)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
32	(3Z)-3-[1H-benzimidazol-2-yl[3-(methoxy)phenyl]methylidene]-5-[[1-ethylpiperidin-4-yl]oxy]-1,3-dihydro-2H-indol-2-one	
33	(3Z)-3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-[[1-ethylpiperidin-4-yl]oxy]-1,3-dihydro-2H-indol-2-one	
34	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-[[1-(phenylmethyl)piperidin-4-yl]oxy]-1,3-dihydro-2H-indol-2-one	






Entry	Name	Structure
35	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one	
36	(3Z)-3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one	
37	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one	
38	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
39	(3Z)-3-[1H-benzimidazol-2-yl(3-(methyloxy)phenyl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	






Entry	Name	Structure
40	(3Z)-3-[(3-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
41	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
42	(3Z)-3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
43	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)(methyl)amino]-1,3-dihydro-2H-indol-2-one	
44	(3Z)-3-[(3-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one	






Entry	Name	Structure
45	(3Z)-3-[1H-benzimidazol-2-yl(4-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
46	(3Z)-3-[1H-benzimidazol-2-yl(3-fluorophenyl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
47	(3Z)-3-[1H-benzimidazol-2-yl(4-fluorophenyl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
48	(3Z)-3-[(3-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
49	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	






Entry	Name	Structure
50	(3Z)-3-[1H-benzimidazol-2-yl(3-fluoro-4-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
51	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
52	(3Z)-3-[1H-benzimidazol-2-yl(4-fluoro-3-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
53	(3Z)-3-[(3-chloro-4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
54	(3Z)-3-[(3,4-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	

Entry	Name	Structure
55	(3Z)-3-[(5-chloro-1H-benzimidazol-2-yl)(phenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
56	(3Z)-3-[(5-chloro-1H-benzimidazol-2-yl)(3,5-difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
57	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluoro-4-methylphenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
58	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
59	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(1H-imidazol-2-yl)(4-propylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one	

Entry	Name	Structure
60	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl[4-(trifluoromethyl)phenyl]methylidene]-1,3-dihydro-2H-indol-2-one	
61	(3E)-3-[(3,5-difluorophenyl)(5-fluoro-1H-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
62	(3Z)-3-[(3,5-difluorophenyl)(5-fluoro-1H-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
63	(3Z)-3-[(3-fluoro-4-methylphenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
64	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-methyl-1H-imidazol-2-yl)(4-methylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one	

Entry	Name	Structure
65	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[3-fluoro-4-(trifluoromethyl)phenyl](1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
66	(3Z)-3-[(4-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
67	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[3-fluoro-4-methylphenyl](4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
68	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[1H-imidazol-2-yl][6-(trifluoromethyl)pyridin-3-yl]methylidene]-1,3-dihydro-2H-indol-2-one	
69	(3Z)-3-[1H-imidazol-2-yl(4-methylphenyl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	






Entry	Name	Structure
70	(3Z)-3-[(3-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
71	(3Z)-3-{1H-imidazol-2-yl[4-(trifluoromethyl)phenyl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
72	(3Z)-3-[(5-chloro-1H-benzimidazol-2-yl)(phenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
73	(3Z)-3-[(3,5-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
74	(3Z)-3-[(3,5-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	






Entry	Name	Structure
75	(3Z)-3-[(3,5-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-([1-[2-(methyloxy)ethyl]piperidin-4-yl]amino)-1,3-dihydro-2H-indol-2-one	
76	(3Z)-3-[(3,5-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-([1-[2-(methyloxy)ethyl]piperidin-4-yl]amino)-1,3-dihydro-2H-indol-2-one	
77	(3Z)-3-[(4-methyl-1H-imidazol-2-yl)(4-methylphenyl)methylidene]-5-([1-[2-(methyloxy)ethyl]piperidin-4-yl]amino)-1,3-dihydro-2H-indol-2-one	
78	(3Z)-3-[(4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-([1-[2-(methyloxy)ethyl]piperidin-4-yl]amino)-1,3-dihydro-2H-indol-2-one	
79	(3Z)-3-[(3,4-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-([1-[2-(methyloxy)ethyl]piperidin-4-yl]amino)-1,3-dihydro-2H-indol-2-one	






Entry	Name	Structure
80	(3Z)-3-[(3-chloro-4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
81	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-(piperidin-4-ylamino)-1,3-dihydro-2H-indol-2-one	
82	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[[1-(2-piperidin-1-ylethyl)piperidin-4-yl]amino]-1,3-dihydro-2H-indol-2-one	
83	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[[1-(2-morpholin-4-ylethyl)piperidin-4-yl]amino]-1,3-dihydro-2H-indol-2-one	
84	(3Z)-5-[(1-[2-(diethylamino)ethyl]piperidin-4-yl)amino]-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	






Entry	Name	Structure
85	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[[1-(2-pyrrolidin-1-ylethyl)piperidin-4-yl]amino]-1,3-dihydro-2H-indol-2-one	
86	(3Z)-3-[1H-imidazol-2-yl(4-methylphenyl)methylidene]-5-[[1-(1-methylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
87	(3Z)-3-[(3-fluorophenyl)(1H-1,2,4-triazol-5-yl)methylidene]-5-[[1-[2-(methyloxy)ethyl]piperidin-4-yl]amino]-1,3-dihydro-2H-indol-2-one	
88	ethyl 2-[(Z)-(3-fluorophenyl)[5-[[1-[2-(methyloxy)ethyl]piperidin-4-yl]amino)-2-oxo-1,2-dihydro-3H-indol-3-ylidene]methyl]-4-methyl-1H-imidazole-5-carboxylate	
89	(3Z)-3-[1H-imidazol-2-yl(phenyl)methylidene]-5-[[1-[2-(methyloxy)ethyl]piperidin-4-yl]amino]-1,3-dihydro-2H-indol-2-one	

Entry	Name	Structure
90	(3Z)-3-{1H-imidazol-2-yl}[4-(methoxy)phenyl]methylidene]-5-({1-[2-(methoxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
91	(3Z)-3-[(4-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-(methoxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
92	(3Z)-3-[[3-fluoro-4-(trifluoromethyl)phenyl](1H-imidazol-2-yl)methylidene]-5-({1-[2-(methoxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
93	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[1-(methylsulfonyl)piperidin-4-yl]amino}-1,3-dihydro-2H-indol-2-one	
94	(3Z)-3-[1H-imidazol-2-yl](4-propylphenyl)methylidene]-5-({1-[2-(methoxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	

Entry	Name	Structure
95	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(4-phenyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
96	(3Z)-3-[(3-fluorophenyl)(4-phenyl-1H-imidazol-2-yl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
97	(3Z)-3-[(3-fluoro-4-methylphenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
98	(3Z)-3-[1H-imidazol-2-yl]-6-(trifluoromethyl)pyridin-3-ylmethylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
99	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(1H-1,2,4-triazol-5-yl)methylidene]-1,3-dihydro-2H-indol-2-one	

Entry	Name	Structure
100	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[2-fluoro-4-(trifluoromethyl)phenyl](1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
101	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[4-methyl-1H-imidazol-2-yl][4-(trifluoromethyl)phenyl]methylidene]-1,3-dihydro-2H-indol-2-one	
102	(3Z)-3-[(4-chlorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
103	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[3-fluoro-4-(trifluoromethyl)phenyl](4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
104	(3Z)-3-[(3,4-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	

Entry	Name	Structure
105	(3Z)-3-[(3-chloro-4-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
106	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
107	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(2-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	 <u>and</u>
108	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[2-fluoro-4-(trifluoromethyl)phenyl](4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
109	(3Z)-3-[(2,3-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	

Entry	Name	Structure
110	(3Z)-3-[(2,3-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
111	(3Z)-3-[(2,4-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
112	(3Z)-3-[(2,4-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
113	(3Z)-3-[(2-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
114	(3Z)-3-[(3-trifluoromethylphenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	

Entry	Name	Structure
115	(3Z)-3-[(3-trifluoromethylphenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
116	(3Z)-3-[(2,4-dichloro-5-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
117	(3Z)-3-[(2,4-dichloro-5-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
118	(3Z)-3-[(4-chloro-2-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	

and a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof

19. **(currently amended)** A pharmaceutical composition comprising a compound according to any one of claims 1-18 claim 1, 9, 12, 13, 18, 31, 32, 33, 34, 35, 36, 37, or 38 or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof, where the compound is optionally as a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

20. (canceled)

21. (canceled)

22. (canceled)

23. (canceled)

24. (currently amended) A method of treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities, the method comprising administering, to a mammal in need thereof, a therapeutically effective amount of the compound of claim 1, 9, 12, 13, 18, 31, 32, 33, 34, 35, 36, 37, or 38 or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof, where the compound is optionally as a pharmaceutically acceptable salt thereof; or comprising administering, to a mammal in need thereof, a therapeutically effective amount of the pharmaceutical composition as described in any one of claims 1-19 of claim 19.

25. (canceled)

26. (canceled)


27. (new) The method of Claim 24 where the disease or disorder is cancer.

28. (new) The method of Claim 27 where the cancer is non-small cell lung cancer, renal cell carcinoma, cancer of the large bowel, gastrointestinal cancer, ovarian cancer, acute myeloid leukemia, and multiple myeloma.

29. (new) The method of Claim 27 where the cancer is selected from squamous cell cancer, undifferentiated large cell cancer, adenocarcinoma, and alveolar (bronchiolar) carcinoma.



30. (new) The method of Claim 24 where the disease or disorder is atherosclerosis.

31. (new) The compound of Claim 7 selected from

10	(3Z)-3-[[5-(methyloxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
----	--	--




25	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
31	(3Z)-5-(8-azabicyclo[3.2.1]oct-3-ylamino)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
60	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-{1H-imidazol-2-yl[4-(trifluoromethyl)phenyl]methylidene}-1,3-dihydro-2H-indol-2-one	
65	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[3-fluoro-4-(trifluoromethyl)phenyl](1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
68	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-{1H-imidazol-2-yl[6-(trifluoromethyl)pyridin-3-yl]methylidene}-1,3-dihydro-2H-indol-2-one	






99	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(1H-1,2,4-triazol-5-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
100	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[2-fluoro-4-(trifluoromethyl)phenyl](1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
101	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-methyl-1H-imidazol-2-yl)[4-(trifluoromethyl)phenyl]methylidene]-1,3-dihydro-2H-indol-2-one	
103	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[3-fluoro-4-(trifluoromethyl)phenyl](4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
108	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[2-fluoro-4-(trifluoromethyl)phenyl](4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	






114	(3Z)-3-[(3-trifluoromethylphenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
115	(3Z)-3-[(3-trifluoromethylphenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	

and a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof, and where the compound is optionally as a pharmaceutically acceptable salt thereof.

32. (new) The compound of Claim 9 selected from

1	(3Z)-3-[[5-(methoxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-5-[[1-(phenylmethyl)pyrrolidin-3-yl]amino]-1,3-dihydro-2H-indol-2-one	
2	(3Z)-5-[(1-ethylpiperidin-3-yl)amino]-3-[[5-(methoxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
30	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-[[1-(methylsulfonyl)piperidin-4-yl]amino]-1,3-dihydro-2H-indol-2-one	






32	(3Z)-3-[1H-benzimidazol-2-yl[3-(methoxy)phenyl]methylidene]-5-[(1-ethylpiperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one	
33	(3Z)-3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one	
34	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-[(1-(phenylmethyl)piperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one	
35	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one	
36	(3Z)-3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-[(1-[2-(methoxy)ethyl]piperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one	

37	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-[2-(methoxy)ethyl]piperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one	
43	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)(methyl)amino]-1,3-dihydro-2H-indol-2-one	
44	(3Z)-3-[(3-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one	
81	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-(piperidin-4-ylamino)-1,3-dihydro-2H-indol-2-one	
93	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[[1-(methylsulfonyl)piperidin-4-yl]amino]-1,3-dihydro-2H-indol-2-one	

and a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof, and where the compound is optionally as a pharmaceutically acceptable salt thereof.

33. (new) The compound of Claim 12 selected from

6	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[5-(methoxy)-1H-benzimidazol-2-yl](4-methylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
12	(3Z)-3-[1H-benzimidazol-2-yl(4-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
13	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl(4-methylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
22	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-(piperidin-4-ylamino)-1,3-dihydro-2H-indol-2-one	
28	2-(2-{2-[(Z)-{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-3H-indol-3-ylidene}(phenyl)methyl]-1H-imidazol-4-yl}ethyl)-1H-isoindole-1,3(2H)-dione	

50	(3Z)-3-[1H-benzimidazol-2-yl(3-fluoro-4-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
52	(3Z)-3-[1H-benzimidazol-2-yl(4-fluoro-3-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
57	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluoro-4-methylphenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
59	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl(4-propylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
63	(3Z)-3-[(3-fluoro-4-methylphenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-[2-(methoxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	






64	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-methyl-1H-imidazol-2-yl)(4-methylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
67	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluoro-4-methylphenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
69	(3Z)-3-[1H-imidazol-2-yl(4-methylphenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
72	(3Z)-3-[(5-chloro-1H-benzimidazol-2-yl)(phenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
86	(3Z)-3-[1H-imidazol-2-yl(4-methylphenyl)methylidene]-5-[(1-methylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	






88	ethyl 2-((Z)-(3-fluorophenyl)[5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-2-oxo-1,2-dihydro-3H-indol-3-ylidene]methyl)-4-methyl-1H-imidazole-5-carboxylate	
94	(3Z)-3-[1H-imidazol-2-yl(4-propylphenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
95	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(4-phenyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
96	(3Z)-3-[(3-fluorophenyl)(4-phenyl-1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	 and
97	(3Z)-3-[(3-fluoro-4-methylphenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	







and a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof, and where the compound is optionally as a pharmaceutically acceptable salt thereof.






34. (new) The compound of Claim 13 selected from






3	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[5-(methoxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
4	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl(phenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
5	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[5-(methoxy)-1H-benzimidazol-2-yl][4-(methoxy)phenyl]methylidene]-1,3-dihydro-2H-indol-2-one	
7	(3Z)-3-[1H-benzimidazol-2-yl(4-nitrophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
8	(3Z)-3-[1H-benzimidazol-2-yl[4-(methoxy)phenyl]methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	



9	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
11	(3Z)-3-[(4-aminophenyl)(1H-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
14	(3Z)-5-[(1-ethylpiperidin-4-yl)oxy]-3-[[5-(methyloxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
15	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-{1H-imidazol-2-yl[4-(methyloxy)phenyl]methylidene}-1,3-dihydro-2H-indol-2-one	
16	(3Z)-3-[1H-benzimidazol-2-yl(4-fluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	

17	(3Z)-3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
18	(3Z)-3-[1H-benzimidazol-2-yl(3-fluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
19	(3Z)-3-[1H-benzimidazol-2-yl(3-nitrophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
21	(3Z)-3-[(3-aminophenyl)(1H-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
23	3-((Z)-1H-benzimidazol-2-yl{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl}benzenecarboximide	

24	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
26	(3Z)-3-{1H-benzimidazol-2-yl[3-(methyloxy)phenyl]methylidene}-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
27	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
29	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-({1-[2-(dimethylamino)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
38	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
39	(3Z)-3-{1H-benzimidazol-2-yl[3-(methyloxy)phenyl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	



45	(3Z)-3-[1H-benzimidazol-2-yl(4-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
46	(3Z)-3-[1H-benzimidazol-2-yl(3-fluorophenyl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
47	(3Z)-3-[1H-benzimidazol-2-yl(4-fluorophenyl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
55	(3Z)-3-[(5-chloro-1H-benzimidazol-2-yl)(phenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
56	(3Z)-3-[(5-chloro-1H-benzimidazol-2-yl)(3,5-difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	






61	(3E)-3-[(3,5-difluorophenyl)(5-fluoro-1H-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
62	(3Z)-3-[(3,5-difluorophenyl)(5-fluoro-1H-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
77	(3Z)-3-[(4-methyl-1H-imidazol-2-yl)(4-methylphenyl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
89	(3Z)-3-[1H-imidazol-2-yl(phenyl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	 and
90	(3Z)-3-[1H-imidazol-2-yl[4-(methyloxy)phenyl]methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	






116	(3Z)-3-[(2,4-dichloro-5-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
117	(3Z)-3-[(2,4-dichloro-5-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	






and a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof, and where the compound is optionally as a pharmaceutically acceptable salt thereof.






35. **(new)** The compound of Claim 16 selected from

40	(3Z)-3-[(3-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
42	(3Z)-3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	

48	(3Z)-3-[(3-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
53	(3Z)-3-[(3-chloro-4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
54	(3Z)-3-[(3,4-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
66	(3Z)-3-[(4-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
73	(3Z)-3-[(3,5-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	






74	(3Z)-3-[(3,5-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
75	(3Z)-3-[(3,5-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
76	(3Z)-3-[(3,5-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
78	(3Z)-3-[(4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
79	(3Z)-3-[(3,4-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	



80	(3Z)-3-[(3-chloro-4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
91	(3Z)-3-[(4-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
102	(3Z)-3-[(4-chlorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
104	(3Z)-3-[(3,4-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
105	(3Z)-3-[(3-chloro-4-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	

109	(3Z)-3-[(2,3-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
110	(3Z)-3-[(2,3-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
111	(3Z)-3-[(2,4-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
112	(3Z)-3-[(2,4-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	 and
118	(3Z)-3-[(4-chloro-2-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	


and a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof, and where the compound is optionally as a pharmaceutically acceptable salt thereof.

36. (new) A compound selected from

20	3-((Z)-1H-benzimidazol-2-yl{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl}benzonitrile	
71	(3Z)-3-{1H-imidazol-2-yl[4-(trifluoromethyl)phenyl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
87	(3Z)-3-[(3-fluorophenyl)(1H-1,2,4-triazol-5-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
92	(3Z)-3-[[3-fluoro-4-(trifluoromethyl)phenyl](1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
98	(3Z)-3-{1H-imidazol-2-yl[6-(trifluoromethyl)pyridin-3-yl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	


	<p>7-[(1<i>H</i>-Benzoimidazol-2-yl)-(3-chloro-phenyl)-methylene]-2-[1-(2-methoxy-ethyl)-piperidin-4-ylamino]-5,7-dihydro-pyrrolo[3,2-<i>d</i>]pyrimidin-6-one</p>	
	<p>E- and Z- of 3-[(1<i>H</i>-Benzoimidazol-2-yl)-(3-chloro-phenyl)-methylene]-5-[1-(2-methoxy-ethyl)-piperidin-4-yloxy]-1,3-dihydro-pyrrolo[3,2-<i>b</i>]pyridin-2-one</p>	

37. (new) The compound of Claim 18 selected from

<p>(3<i>Z</i>)-3-[(2-fluorophenyl)(4-methyl-1<i>H</i>-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2<i>H</i>-indol-2-one</p>	
---	---

and a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

38. (new) The compound of Claim 18 selected from

<p>(3<i>Z</i>)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(4-methyl-1<i>H</i>-imidazol-2-yl)methylidene]-1,3-dihydro-2<i>H</i>-indol-2-one</p>	
---	--

and a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.